Greg J. Haro, MD Named a 2019 STAT Wunderkind

Greg J. Haro, MD, a general surgery resident at UCSF, has been named a 2019 STAT Wunderkind by STAT News, a journal that reports the latest in health, medicine, and scientific discoveries. This prestigious award is given to early-career scientists who are performing groundbreaking research.

Dr. Haro is currently a PGY-4 general surgery resident who completed a postdoctoral research fellowship in the UCSF Thoracic Oncology Lab. His work, featured in his STAT Wunderkind piece, is dedicated to the modernization of lung cancer staging based upon the incorporation of patient-specific gene expression patterns. Dr. Haro stated, “one of the greatest limitations to conventional lung cancer staging has been its inability to differentiate high-risk patients likely to harbor occult disease after surgical resection from low-risk patients who have been more likely cured by surgery alone”. Through incorporation of tumor biology, Dr. Haro’s work may assist in determining which patients would benefit from additional treatment.

Dr. Haro’s research is supported by Johannes Kratz, MD and David Jablons, MD. Dr. Kratz is the Van Auken Endowed Chair in Thoracic Oncology, Director of Minimally Invasive and Robotic Thoracic Surgery, and Associate Director of the Thoracic Surgery Residency Program. Dr. Jablons is the Nan T. McEvoy Distinguished Professor of Thoracic Surgical Oncology, Ada Distinguished Professor of Thoracic Oncology, Program Leader in Thoracic Oncology, Director of the Thoracic Oncology Laboratory, and Chief of General Thoracic Surgery at UCSF.